These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1456499)

  • 1. [Modified LDL and atherosclerosis. Nature of modifications. Physicochemical and biological properties].
    Pech MA; Myara I; Vedie B; Moatti N
    Ann Biol Clin (Paris); 1992; 50(4):213-27. PubMed ID: 1456499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein modification occurring in human plasma possible mechanism of in vivo lipoprotein desialylation as a primary step of atherogenic modification.
    Tertov VV; Kaplun VV; Sobenin IA; Orekhov AN
    Atherosclerosis; 1998 May; 138(1):183-95. PubMed ID: 9678784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonoxidative modifications of lipoproteins in atherogenesis.
    Tabas I
    Annu Rev Nutr; 1999; 19():123-39. PubMed ID: 10448519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of methylglyoxal on the physico-chemical and biological properties of low-density lipoprotein.
    Schalkwijk CG; Vermeer MA; Stehouwer CD; te Koppele J; Princen HM; van Hinsbergh VW
    Biochim Biophys Acta; 1998 Nov; 1394(2-3):187-98. PubMed ID: 9795211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants.
    Aviram M
    Eur J Clin Chem Clin Biochem; 1996 Aug; 34(8):599-608. PubMed ID: 8877334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified forms of low density lipoprotein and atherosclerosis.
    Aviram M
    Atherosclerosis; 1993 Jan; 98(1):1-9. PubMed ID: 8457244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and anti-oxidants in arterial cells and blood lipoproteins.
    Aviram M
    Antioxid Redox Signal; 1999; 1(4):585-94. PubMed ID: 11233155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Atherogenic modification of low-density lipoproteins].
    Sukhorukov VN; Karagodin VP; Orekhov AN
    Biomed Khim; 2016 May; 62(4):391-402. PubMed ID: 27562992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative reactivity of the myeloperoxidase-derived oxidants HOCl and HOSCN with low-density lipoprotein (LDL): Implications for foam cell formation in atherosclerosis.
    Ismael FO; Proudfoot JM; Brown BE; van Reyk DM; Croft KD; Davies MJ; Hawkins CL
    Arch Biochem Biophys; 2015 May; 573():40-51. PubMed ID: 25795019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of lipid peroxidation and antioxidants in oxidative modification of LDL.
    Esterbauer H; Gebicki J; Puhl H; Jürgens G
    Free Radic Biol Med; 1992 Oct; 13(4):341-90. PubMed ID: 1398217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin increases macrophage uptake of oxidized low density lipoprotein.
    Aviram M; Fuhrman B; Maor I; Brook GJ
    Eur J Clin Chem Clin Biochem; 1992 Feb; 30(2):55-61. PubMed ID: 1581411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acrolein-conjugated low-density lipoprotein induces macrophage foam cell formation.
    Watanabe K; Nakazato Y; Saiki R; Igarashi K; Kitada M; Ishii I
    Atherosclerosis; 2013 Mar; 227(1):51-7. PubMed ID: 23305793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation.
    Holvoet P; Perez G; Bernar H; Brouwers E; Vanloo B; Rosseneu M; Collen D
    J Clin Invest; 1994 Jan; 93(1):89-98. PubMed ID: 8282826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial metabolism of lipoproteins in relation to atherogenesis.
    Steinberg D
    Ann N Y Acad Sci; 1990; 598():125-35. PubMed ID: 2248432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis.
    Parthasarathy S; Steinberg D; Witztum JL
    Annu Rev Med; 1992; 43():219-25. PubMed ID: 1580586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
    Chapman MJ; Guérin M; Bruckert E
    Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative modification of lipoproteins.
    Arai H
    Subcell Biochem; 2014; 77():103-14. PubMed ID: 24374922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum lipoprotein and atherogenicity--relationship with particle size and composition of low density lipoproteins, and their modifications by oxidation and glycation].
    Takeuchi N; Saheki S
    Rinsho Byori; 1995 Aug; 43(8):753-62. PubMed ID: 7474432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Front line of oxidized lipoproteins: role of oxidized lipoproteins in atherogenesis and cardiovascular disease risk].
    Yoshida H
    Rinsho Byori; 2010 Jun; 58(6):622-30. PubMed ID: 20662275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The low density lipoprotein and low density lipoprotein receptors and their possible importance in the pathogenesis of atherosclerosis.
    Dresel HA; Friedrich EA; Otto I; Waldherr R; Schettler G
    Arzneimittelforschung; 1985; 35(12A):1936-40. PubMed ID: 3913426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.